Literature DB >> 29623443

Pharmacokinetic and Pharmacodynamic Considerations of Antibiotics of Last Resort in Treating Gram-Negative Infections in Adult Critically Ill Patients.

Mojdeh S Heavner1, Kimberly C Claeys2, Anne M Masich1, Jeffrey P Gonzales1.   

Abstract

PURPOSE OF REVIEW: We provide an overview of antimicrobials that are considered last resort for the treatment of resistant gram-negative infections in adult critically ill patients. The role in therapy, pharmacodynamic (PD) goals, and pharmacokinetic (PK) changes in critical illness for aminoglycosides, polymyxins, tigecycline, fosfomycin, and fluoroquinolones are summarized. RECENT
FINDINGS: Altered PK in septic patients in the intensive care unit (ICU) is observed with many of our agents of last resort. Based on the available literature, dosage adjustments may be required to optimize PK parameters and meet PD targets for most effective bacterial killing. Data is limited, studies are conducted in heterogeneous patient populations, and conclusions are frequently conflicting. Strategic dosing regimens such as high-dose extended interval dosing of aminoglycosides or loading doses with colistin and polymyxin B are examples of ways to optimize antibiotic PK in critically ill patients. Benefits of these strategies must be balanced with risks of increased toxicity. Patients with resistant gram-negative infections may present with septic shock in the ICU. Sepsis can significantly alter the PK of antibiotics and require dosage adjustments to attain optimal drug levels. An understanding of PK and PD properties of these agents of last resort will help to maximize therapeutic efficacy while minimizing toxic effects.

Entities:  

Keywords:  Aminoglycosides; Fluoroquinolones; Fosfomycin; ICU; Polymyxins; Tigecycline

Year:  2018        PMID: 29623443     DOI: 10.1007/s11908-018-0614-0

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  100 in total

Review 1.  The revival of fosfomycin.

Authors:  Argyris S Michalopoulos; Ioannis G Livaditis; Vassilios Gougoutas
Journal:  Int J Infect Dis       Date:  2011-09-25       Impact factor: 3.623

2.  Pharmacokinetics and total removal of fosfomycin in two patients undergoing intermittent haemodialysis and extended dialysis: prescription needs to avoid under-dosing.

Authors:  Julius J Schmidt; Stefanie M Bode-Böger; Michaela Wilhelmi; Mohamed Omar; Jens Martens-Lobenhoffer; Tobias Welte; Jan T Kielstein
Journal:  J Antimicrob Chemother       Date:  2016-06-05       Impact factor: 5.790

3.  The unpredictability of serum concentrations of gentamicin: pharmacokinetics of gentamicin in patients with normal and abnormal renal function.

Authors:  D Kaye; M E Levison; E D Labovitz
Journal:  J Infect Dis       Date:  1974-08       Impact factor: 5.226

Review 4.  Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability.

Authors:  Federico Pea; Pierluigi Viale; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

5.  The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia.

Authors:  R D Moore; C R Smith; P S Lietman
Journal:  J Infect Dis       Date:  1984-03       Impact factor: 5.226

6.  Single-dose pharmacokinetics of fosfomycin during continuous venovenous haemofiltration.

Authors:  Rainer Gattringer; Brigitte Meyer; Gottfried Heinz; Claudia Guttmann; Markus Zeitlinger; Christian Joukhadar; Peter Dittrich; Florian Thalhammer
Journal:  J Antimicrob Chemother       Date:  2006-06-16       Impact factor: 5.790

7.  Tigecycline combination for ventilator-associated pneumonia caused by extensive drug-resistant Acinetobacter baumannii.

Authors:  Hangyong He; Yali Zheng; Bing Sun; Xiao Tang; Rui Wang; Zhaohui Tong
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

8.  Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections.

Authors:  J A Passarell; A K Meagher; K Liolios; B B Cirincione; S A Van Wart; T Babinchak; E J Ellis-Grosse; P G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2007-10-22       Impact factor: 5.191

9.  The role of tigecycline in the treatment of infections in light of the new black box warning.

Authors:  Deepali Dixit; Rani Patel Madduri; Roopali Sharma
Journal:  Expert Rev Anti Infect Ther       Date:  2014-03-06       Impact factor: 5.091

10.  A study of once-daily amikacin with low peak target concentrations in intensive care unit patients: pharmacokinetics and associated outcomes.

Authors:  Flora Bacopoulou; Sophia L Markantonis; Elias Pavlou; Maria Adamidou
Journal:  J Crit Care       Date:  2003-06       Impact factor: 3.425

View more
  3 in total

1.  The Kinetics of an Antibiotic Stewardship Intervention: A Quasi-Experimental Study.

Authors:  Tali Shafat; Orly Shimoni; Anna Nikonov; Lior Nesher
Journal:  Infect Dis Ther       Date:  2021-01-30

2.  Commentary: Population pharmacokinetics of colistin sulfate in critically ill patients: Exposure and clinical efficacy.

Authors:  Huadong Chen; Piaopiao Li
Journal:  Front Pharmacol       Date:  2022-09-09       Impact factor: 5.988

3.  A One Health Comparative Assessment of Antimicrobial Resistance in Generic and Extended-Spectrum Cephalosporin-Resistant Escherichia coli from Beef Production, Sewage and Clinical Settings.

Authors:  Emelia H Adator; Claudia Narvaez-Bravo; Rahat Zaheer; Shaun R Cook; Lisa Tymensen; Sherry J Hannon; Calvin W Booker; Deirdre Church; Ron R Read; Tim A McAllister
Journal:  Microorganisms       Date:  2020-06-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.